Innovation

Aqemia, spin-off ENS - PSL, receives support and funding from Sanofi to apply its disruptive technology against COVID-19

Le
Aqemia is a spin-off startup from the École normale supérieure – PSL, specialized in drug discovery. On December 10, it received support and funding from Sanofi, a leader in the pharmaceutic industry, to apply its disruptive technology to design and evaluate new innovative molecules against coronavirus.
Emmanuelle Martiano et Maximilien Levesque, chercheur au département de chimie de l’ENS-PSL, confondateurs d'Aqemia

Aqemia was founded in 2019 thanks to the intensive work with the PSL Valorisation team and the funding from PSL Innovation Fund. The start-up, a spin-off from ENS - PSL, was founded by Emmanuelle Martiano et Maximilien Levesque, a researcher at the ENS-PSL's chemistry department; Aqemia's strenght lies on the use of machine learning and unique algorithms derived from theoretical physics to invent innovative molecules.

On December 10, 2020, Aqemia received support and funding from Sanofi to apply its disruptive technology against COVID-19. The deeptech startup joined the battle against the Covid from the start and positioned its technology to design and test new molecules. Aqemia's research now benefit from the support of a leader in the pharmaceutic industry. As part of the agreement, Aqemia will apply its generative AI combined with its disruptive proprietary algorithms for affinity calculation between therapeutic targets and drug candidates against the coronavirus protease.

[ENS - PSL ] How to design new therapies with the combination of AI and theoretical physics